Caladrius Biosciences, Inc.
If you purchased Caladrius Biosciences, Inc. securities and would like to join the action, please click "Join This Action" below.
CLBS STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE MERGER OF CALADRIUS BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS
April 27, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Caladrius Biosciences, Inc. (NASDAQ: CLBS) and Cend Therapeutics, Inc. is fair to Caladrius shareholders. Upon closing of the proposed merger, Cend shareholders will receive approximately 60.5 million shares of Caladrius common stock, subject to certain closing conditions, resulting in the shareholders of each company owning approximately 50% of the combined company.
The investigation concerns whether Caladrius and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Caladrius shareholders; and (2) disclose all material information necessary for Caladrius shareholders to adequately assess and value the merger consideration. On behalf of Caladrius shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.